What type of study is this?

Adalimumab for the treatment of hidradenitis suppurativa: evaluation of clinical response and impact on inflammatory markers

View Full Paper

Ask AI

Bookmark

Authors

Retrospective cohort evaluated adalimumab's effect on inflammatory markers in hidradenitis suppurativa, revealing significant improvement.

Adalimumab treatment significantly reduced inflammatory markers in patients with hidradenitis suppurativa.
Statistical analysis showed significant improvements in clinical scores, including DLQI and IHS4.
NLR, PLR, and CRP levels exhibited significant decreases post-adalimumab treatment.
Most patients did not achieve a 55% reduction in IHS4-55 scores, suggesting varied treatment responses.

Arce et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective cohort evaluated adalimumab's effect on inflammatory markers in hidradenitis suppurativa, revealing significant improvement.